Drugs.com - Clinical Trials

Kura Oncology and Kyowa Kirin Announce Positive Ziftomenib Monotherapy Registrational Trial and Positive FDA Feedback for Upcoming Frontline Combination Trial Designs

SAN DIEGO, Feb. 05, 2025 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA, “Kura”) and Kyowa Kirin Co., Ltd. (TSE: 4151, “Kyowa Kirin”) today announced positive topline results from KOMET-001, the Phase 2...

Feb 9, 2025 - 21:44
 0
Kura Oncology and Kyowa Kirin Announce Positive Ziftomenib Monotherapy Registrational Trial and Positive FDA Feedback for Upcoming Frontline Combination Trial Designs
SAN DIEGO, Feb. 05, 2025 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA, “Kura”) and Kyowa Kirin Co., Ltd. (TSE: 4151, “Kyowa Kirin”) today announced positive topline results from KOMET-001, the Phase 2...
Read More

Tags:

Previous Article

Adicet Bio Receives FDA Fast Track Designation for ADI-001 for the Treatment of ...

Next Article

March Biosciences Receives FDA Orphan Drug Designation for MB-105, a First-in-Cl...

Related Posts

EyePoint Announces Positive Six-Month Results for the Phase 2 VERONA Clinical Trial of Duravyu for Diabetic Macular Edema Meeting Primary and Secondary Endpoints

EyePoint Announces Positive Six-Month Results for the P...

Feb 9, 2025  0

Datopotamab Deruxtecan Granted Priority Review in the US for Patients with Previously Treated Advanced EGFR-Mutated Non-Small Cell Lung Cancer

Datopotamab Deruxtecan Granted Priority Review in the U...

Feb 9, 2025  0

Opus Genetics Announces FDA Fast Track and Enrollment Updates for Phentolamine Ophthalmic Solution 0.75% Programs

Opus Genetics Announces FDA Fast Track and Enrollment U...

Feb 27, 2025  0